use monoclonal antibodies deliver radioisotopes directly tumor cells promising strategy enhance antitumor effects native antibodies emitted decay radioisotopes differ significant ways proper selection isotope antibody combinations crucial making radioimmunotherapy standard therapeutic modality short pathlength microm high linear energy transfer approximately NUMBER radioisotopes targeted therapy offers potential specific tumor cell killing damage surrounding normal tissues properties make targeted therapy ideal elimination minimal residual micrometastatic disease radioimmunotherapy using 213bi 211at 225ac shown activity vitro vivo experimental models clinical trials demonstrated safety feasibility activity targeted therapy treatment cytoreduced disease advances require investigation potent isotopes new sources methods isotope production improved chelation techniques better methods pharmacokinetic dosimetric modeling new methods isotope delivery pretargeting treatment patients disease ultimately randomized trials comparing targeted therapy standard approaches required determine clinical utility approach references NUMBER alpha beta particles NUMBER NUMBER alpha emitting alpha particle beta emitters alpha particle alpha emitters alpha particle small volume advanced alpha particle kev microm